Walter Reinisch, MD
Professor, Division of Gastroenterology, Department of Medicine
Chairholder, Audrey Campbell Chair in Ulcerative Colitis Research
Associate Professor, Gastroenterology, Division of Gastroenterology & Hepatology, Medical University of Vienna
Dr. Reinisch, MD, graduated at the Medical University of Vienna (MUV), where he finished his training in Internal Medicine and Gastroenterology. After initial scientific studies in oncology at the MUV and the National Cancer Institute, Frederick, MD, he decided to focus his research interest on inflammatory Bowel disease (IBD). Dr. Reinisch is founding member of the European Crohn’s & Colitis Organisation (ECCO) and was assigned as honorary member after having contributed in various positions. He was active in the Scientific and Public Affairs Committee of the United European Gastroenterology (UEG) and headed the Austrian IBD Study Group. Dr. Reinisch is member of the International Organization For the Study of Inflammatory Bowel Disease (IOIBD).
Dr. Reinisch is an expert in designing, conducting and interpreting the results of clinical trials in IBD. He envisions a customized management of IBD utilizing the innovations of translational medicine. He advocates the implementation of a “common language of inflammatory bowel disease” to improve the communication with patients and between physicians for a better care and more robust research outcomes.
- Kumar, N, Leonzino, M, Hancock-Cerutti, W, Horenkamp, FA, Li, P, Lees, JA et al.. VPS13A and VPS13C are lipid transport proteins differentially localized at ER contact sites. J. Cell Biol. 2018; :. doi: 10.1083/jcb.201807019. PubMed PMID:30093493 .
- Hanauer, S, Panaccione, R, Danese, S, Cheifetz, A, Reinisch, W, Higgins, PDR et al.. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients with Ulcerative Colitis. Clin. Gastroenterol. Hepatol. 2018; :. doi: 10.1016/j.cgh.2018.07.009. PubMed PMID:30012431 .
- Eger, NA, Reinisch, E. The impact of one's own voice and production skills on word recognition in a second language. J Exp Psychol Learn Mem Cogn. 2018; :. doi: 10.1037/xlm0000599. PubMed PMID:29985041 .
- Reinisch, W, Colombel, JF, Gibson, PR, Rutgeerts, P, Sandborn, WJ, Tarabar, D et al.. Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab. Inflamm. Bowel Dis. 2018; :. doi: 10.1093/ibd/izy229. PubMed PMID:29982631 .
- Telesco, SE, Brodmerkel, C, Zhang, H, Kim, LL, Johanns, J, Mazumder, A et al.. Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-label Trial of Patients With Ulcerative Colitis. Gastroenterology. 2018; :. doi: 10.1053/j.gastro.2018.06.077. PubMed PMID:29981298 .
- Reinisch, W, Gibson, PR, Sandborn, WJ, Feagan, BG, Strauss, R, Johanns, J et al.. Long-term Benefit of Golimumab for Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension. J Crohns Colitis. 2018; :. doi: 10.1093/ecco-jcc/jjy079. PubMed PMID:29917070 .
- Narula, N, Alshahrani, AA, Yuan, Y, Reinisch, W, Colombel, JF. Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis-a Systematic Review and Meta-Analysis. Clin. Gastroenterol. Hepatol. 2018; :. doi: 10.1016/j.cgh.2018.06.015. PubMed PMID:29913273 .
- Rüland, AM, Hagemann, F, Reinisch, M, Holtschmidt, J, Kümmel, A, Dittmer-Grabowski, C et al.. Using a New Marker Clip System in Breast Cancer: Tumark Vision® Clip - Feasibility Testing in Everyday Clinical Practice. Breast Care (Basel). 2018;13 (2):116-120. doi: 10.1159/000486388. PubMed PMID:29887788 PubMed Central PMC5981593.
- D'Haens, G, Reinisch, W, Panaccione, R, Satsangi, J, Petersson, J, Bereswill, M et al.. Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry. Am. J. Gastroenterol. 2018;113 (6):872-882. doi: 10.1038/s41395-018-0098-4. PubMed PMID:29867173 .
- Reinisch, W, Hung, K, Hassan-Zahraee, M, Cataldi, F. Targeting endothelial ligands: (ICAM-1/Alicaforsen, MAdCAM-1). J Crohns Colitis. 2018; :. doi: 10.1093/ecco-jcc/jjy059. PubMed PMID:29757363 .